Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
Date:12/10/2008

- Three Bavituximab Phase II Cancer Trials and the Company's Other Clinical Programs All Advanced During the Quarter -

- Significant Validation Achieved for Bavituximab and Peregrine's Anti-PS Anti-Viral Platform in Nature Medicine Publication -

- Company Enters into Loan Agreement for Up to $10 Million in Funding -

TUSTIN, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the second quarter of fiscal year (FY) 2009 ended October 31, 2008. Separately, the company also announced today that it has entered into a loan agreement for up to $10 million in funding to help finance its ongoing clinical development programs for the treatment of cancer and serious viral infections.

Peregrine reported a consolidated net loss of $4,497,000, or $0.02 per basic and diluted share, compared to a consolidated net loss of $6,207,000, or $0.03 per basic and diluted share for the same prior year period, a decrease of 28%. The net loss decline of $1,710,000 reflects decreased costs in many areas of Peregrine's business, including research and development and selling, general and administrative expenses.

Total revenues for the current quarter were $1,941,000 compared to $1,892,000 for the comparable quarter last year. Revenues were generated from contract manufacturing services provided by Avid Bioservices and from Peregrine's contract with the U.S. Defense Threat Reduction Agency (DTRA) to evaluate bavituximab for the treatment of viral hemorrhagic fever infections. Contract manufacturing revenues generated by Avid were $983,000 for the current quarter compared to $1,863,000 for the comparable prior year quarter. This decrease in Avid revenues is primarily due to the timing of product shipments to customers,
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
11. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... With a membership increas...s this achievement not only as a milestone in its ...quo;s relevance. Most associations are experiencin...onomy.,“At a time when trade organizations ..., the FMA is experiencing unprecedented growth, si...
(Date:12/3/2009)..., , PLAINSBORO, N.J., Dec. 3 /PRNewswire/ ... Princeton at Plainsboro (UMCPP) reached a milesto...e completion of steel-frame construction at the ne...nter at Princeton (UMCP). ,, (Photo: http://ww..., A topping out ceremony is a steelworkers, tradit...
(Date:12/3/2009)..., , BEIJING, Dec. 3 /PRNewswire-Asia/ ...nefits, ginger, one of the most important ingredie...n China during this flu season. , The tim...supply shortages,effecting upward price pressures...otential repeat of the current demand hysteria ove...
(Date:12/3/2009)..., , WASHINGTON, Dec. 3 /PRNewswire-USNewswir...es for the Aging (AAHSA) commends the Senate for p...which reassures seniors by protecting guaranteed b...gs within the program. ,, "With the silver tsun...s important for health care reform legislation cur...
(Date:12/3/2009)...etformin outperforms widely used sulfonylureas, bu... , THURSDAY, Dec. 3 (HealthDay News) -- A ...ith type 2 diabetes is associated with a higher ri...ment metformin, researchers say. , , Sulfonylur...med less well than metformin in a study of oral an...
Breaking Medicine News(10 mins):Health News:Florida Medical Association Marks Record Membership Growth 2Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 2Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 3Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 4Health News:Ginger Prices Could Skyrocket on H1N1 Fears 2Health News:Diabetes Drugs Go Head-to-Head in Study 2Health News:Diabetes Drugs Go Head-to-Head in Study 3
...ger Institute will commemorate World,Autism Awaren...he one-year anniversary of the Interactive Autism ... , Launched in April 2007 by the Kennedy Krieger ... an online network that links parents to researche...
... health campaign created by an alliance of nationa...ched today in Washington, DC. The program,called E...difficult process,of quitting, and guide them to v...lth organizations aligned to,get a smoking cessati...
...d Focus on Delivering on 200... 31 LodgeNet,Interactive Corporation (Nasdaq: LN...ty solutions to hospitality and healthcare busines...discuss its,progress in creating and driving its s...
...open,the door on Congressional proceedings and oth...day is doing for medical professionals via its liv...ces., MedPage Today is the innovative source of m...April 1, 2008, MedPage Today will be broadcasting,...
...ding,innovator of physiological monitoring solutio...of interoperability with other medical equipment.,... innovative technologies,that facilitate informati...t healthcare and technology companies in,the world...
...ity-based registry of patients treated with drug-e...how long patients with complex coronary artery dis...ke clopidogrel, a drug that prevents unwanted bloo... of which represents off-label use of sirolimus-el...
Other Medicine News:Health News:First national autism registry shows notable impact on autism research in opening year 2Health News:New National Public Health Program Shows Smokers How to Become an EX 2Health News:New National Public Health Program Shows Smokers How to Become an EX 3Health News:New National Public Health Program Shows Smokers How to Become an EX 4Health News:New National Public Health Program Shows Smokers How to Become an EX 5Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 2Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 3Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 4Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 5Health News:MedPage Today(R) Provides First-Time Live Video Coverage of Medical Meeting Press Conferences 2Health News:Nonin Medical, Inc. Is Recognized for Its Role in Promoting Interoperability 2Health News:Matrix registry probes adherence to clopidogrel at 1 year 2Health News:Matrix registry probes adherence to clopidogrel at 1 year 3
(Date:12/3/2009)...RNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc....Falberg has been appointed Senior Vice President a... Jazz Pharmaceuticals more than 20 years of financ...maceutical,s CFO, Ms. Falberg will be responsible ...inancial planning, investor relations, and treasur...
(Date:12/3/2009)...ewswire-FirstCall/ -- ULURU Inc. (NYSE ULU) a...., one of the major pharmaceutical distributors in...one of its suppliers and has placed its first sign...Surgical delivers a comprehensive offering of medi...h care technology-related services to the alternat...
(Date:12/3/2009)...Newswire-FirstCall/ -- Stryker Corporation (NYSE: ...s has authorized the Company to repurchase up to $...ng and amount of any purchases will be determined ...ion of market conditions, stock price and other fa...ions. Purchases may be made from time to time in ...
Breaking Medicine Technology:ULURU Inc. Obtains Status of Approved Supplier With McKesson. 2Stryker Announces $750 Million Share Repurchase Program and Declares a $0.15 Per Share Quarterly Dividend 2Physician Hospitals 28PHA 29 Responds to TIME Magazine Article 3A Filled With Incorrect Assumption and Innuendo 51747 1Physician Hospitals 28PHA 29 Responds to TIME Magazine Article 3A Filled With Incorrect Assumption and Innuendo 51747 2Physician Hospitals 28PHA 29 Responds to TIME Magazine Article 3A Filled With Incorrect Assumption and Innuendo 51747 3Physician Hospitals 28PHA 29 Responds to TIME Magazine Article 3A Filled With Incorrect Assumption and Innuendo 51747 4FertilityAuthority Introduces E Newsletter The Daily Shot 51744 1FertilityAuthority Introduces E Newsletter The Daily Shot 51744 2MultiNational Underwriters Is Now HCC Medical Insurance Services 51740 1MultiNational Underwriters Is Now HCC Medical Insurance Services 51740 2
...1012 coadministered with statins for only five wee...els achieved with,statins alone, with similarly fa...RLEANS and CARLSBAD, Calif., March 26, 2007,/PRNew...ounced new,results from its Phase 2 clinical trial...ted today at the of Cardiology,Annual Scientific S...
...sentation of Comparative Data from ECLIPSE, Larges...gents, NEW ORLEANS, March 27, 2007 /PRNewswire-Fir...al drug Cleviprex(TM) (clevidipine),compared to cu...olling perioperative hypertension -- a potentially...during and/or after,surgery -- were presented for ...
Other Medicine Technology:Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 2Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 3Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 4Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 5
Fine Tying Forceps
Bechert-McPherson Tying Forceps
Microsurgical straight forceps
Girard straight tying forceps
Medicine Products: